Neurona Therapeutics
Neurona Therapeutics is a clinical-stage biotherapeutics company in South San Francisco, California, developing allogeneic regenerative neural cell therapies that permanently integrate into neural circuits to treat chronic disorders of the nervous system. Founded on nearly two decades of stem cell research from the University of California, San Francisco, its lead candidate NRTX-1001 (rezanecel) is an inhibitory interneuron cell therapy delivered as a single, minimally invasive dose for drug-resistant mesial temporal lobe epilepsy, and is advancing through the NTE001 and NTE002 studies toward the Phase 3 EPIC trial. UCB completed its acquisition of Neurona on June 2, 2026. The company publishes no public API, developer program, SDK, or machine-readable specification; its public surface is corporate and clinical, not developer-facing.
Neurona Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Cell Therapy, and Regenerative Medicine.
Neurona Therapeutics’ developer surface includes product news and 16 more developer resources.
Kin Score
Pricing Plans 1
Published pricing tiers and plan structures.
Rate Limits 1
Documented rate limits and quota policies.
Neurona Therapeutics Rate Limits
RATE LIMITSSecurity Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 2
Status, limits, changes, and where to get help
Commercial 3
Pricing, plans, and the legal terms of use
Company 4
The organization behind the API
Other 6
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.